FMP
NASDAQ
14.76 USD
0.21 (1.42%)
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Healthcare
Biotechnology
https://pliantrx.com
NASDAQ
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an ...
0001746473
US7291391057
729139105
260 Littlefield Avenue
650 481 6770
US
158
Jun 3, 2020
0001746473
NASDAQ
Biotechnology
Healthcare
729139105
US7291391057
US
14.76
1.14
409.57k
889.13M
-
12.605-30.85
0.84
-
-
-
-
-5.37
-
https://pliantrx.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.